Shruti Bhat PhD, MBA, Lean Six Sigma Black Belt
  • Home
  • About Shruti
  • Consulting
  • Workshops
  • Patents
  • Articles
    • Case Studies
    • Innovation Portfolio Development & Patents
    • Drugs-in-the- making
    • Culture Change & Business Transformation
    • Operational Excellence, Quality & Continuous Improvement
  • Books
  • Digital
  • Blog
  • Videos
  • Contact

Pharma regulatory- QA updates

1/3/2010

0 Comments

 
Report says information technology may improve medication adherence among older adults.
Information technology is key to improving medication-related errors and improving medication adherence among older adults, according to a recent report  from the Center for Technology and Aging in Oakland, CA. According to the report, "'widespread use' of technology aimed at this population could save thousands of lives and billions of dollars."

Column offers advice on treatment with bone-enhancing drugs.
Who should be treated with bone-enhancing drugs? Until recently, many doctors and drug companies that make these medications were saying almost everyone -- especially older white women, who are at highest risk of one day suffering an osteoporotic fracture." However, "the drugs currently available to enhance bone density" are "expensive...can have side effects, and they are only about 50 percent effective at preventing fractures." Brody suggests that patients with osteopenia should rely instead upon their FRAX risk assessment score, a "bone mineral density test," and their physician's guidance to weigh "possible risks...against known benefits" before starting treatment with such medicines.

Arena seeks FDA approval of weight loss drug.
The first of a new class of obesity drugs moved one step closer to the market as Arena Pharmaceuticals Inc. said it filed for approval of its drug candidate lorcaserin." If approved, the drug is likely to "compete against Vivus Inc.'s Qnexa and Orexigen Therapeutics Inc.'s Contrave32, both of which are still in development." According to Arena, two late-stage trials showed that obese and overweight patients with type 2 diabetes taking lorcaserin experienced significant weight loss, and that the drug was safe and tolerable.

The results appear to meet one of two FDA-recommended goals for obesity drugs: that at least 35 percent of patients taking its drug lose at least five percent of their body weight, and that the group is approximately double the percentage of patients with similar weight loss on the placebo.

Shire seeks full FDA approval of Replagal.
British drug-maker Shire allegedly filed for US marketing approval of its Fabry's disease treatment Replagal [agalsidase alfa]." The drug is currently "available under Food and Drug Administration restrictions.Shire established an early access program in the midst of a shortage in treatments marketed in the US for Fabry disease. The shortages have been caused by the temporary shutdown last summer of Genzyme's Allston Landing manufacturing plant, where the company discovered a virus in a bioreactor in June. If approved, the drug "would compete against" Genzyme's Fabrazyme [algasidase beta].

Follow Shruti on Twitter, Facebook, YouTube, LinkedIn
0 Comments

Your comment will be posted after it is approved.


Leave a Reply.

    Shruti Bhat, global leader in business turnaround, operational excellence and continuous improvement

    New Book Released!

    top ten strategic decision-making tools for operational excellence

    Shruti's YouTube Channel ...

    Picture

    Blog Categories

    All
    3D Printing
    5S
    Agile
    Artificial Intelligence
    Automation
    Balanced Score Card
    Biotechnology
    Books
    Business Turnaround
    Case Studies
    Change Management
    Chemical Industry
    CMMI
    Continuous Improvement
    Design Thinking
    Digitalization
    Drug Delivery
    External News Links
    Food Industry
    Hall Of Fame
    Healthcare
    Hoshin Kanri
    HR Development
    Innovation
    ISO
    Just In Time
    Kaizen
    Leadership
    LEAN
    Lean Six Sigma
    Life Sciences
    Machine Learning
    Manufacturing
    Medical Devices
    Mistake Proofing
    Motivational Cards
    Nanotechnology
    Operations
    Packaging
    Patents
    Personal Products
    Process Improvement
    Product Development
    Productivity Increase
    QbD
    Quality Management
    Robotics
    Scrum
    Service Industry
    Six Sigma
    Strategy
    Supply Chain Logistics
    Telecom Industry
    TQM
    Videos
    Voice Of Customer
    Workshops

    Shruti's books...

    Picture
    shruti bhat, business process management, continuous improvement
    kaizen for pharmaceutcials, medical devices and biotech industry book by Dr Shruti Bhat
    Book on Continuous improvement tools by Dr Shruti Bhat
    kaizen for leaders, continuous process improvement tool to increase profit and organizational excellence by shruti bhat
    kaizen, shruti bhat, continuous improvement, quality, operations management
    Picture
    how to overcome challenges of creating effective teams
    how to lead a successful business transformation

    ​Micro-Learning
    ​Partner

    Picture

    Publishing Partner

    fast read books, business management books, health and wellness books, spiritual guidance books, best online book store

    Wellness
    ​Partner

    Picture
© Copyright 1992- 2022 Dr. Shruti Bhat ALL RIGHTS RESERVED.
See Terms and Conditions for details on this site usage.
SHRUTI BHAT, CONTACT
Click to connect.
Created by Macro2Micro Media